Edward J Stepanski

Summary

Affiliation: Supportive Oncology Services
Country: USA

Publications

  1. ncbi request reprint Controversies in the measurement of daytime sleepiness
    Edward J Stepanski
    Sleep Med Rev 6:79-81. 2002
  2. pmc Improving the utility of interpreting sleep fragmentation
    Edward J Stepanski
    Accelerated Community Oncology Research Network, Memphis, TN 38138, USA
    J Clin Sleep Med 3:275-6. 2007
  3. pmc The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer
    Edward J Stepanski
    Accelerated Community Oncology Research Network, 1770 Kirby Parkway, Suite 400, Memphis, TN 38138, USA
    J Clin Sleep Med 5:132-6. 2009
  4. doi request reprint The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting
    Edward J Stepanski
    ACORN Research, LLC, Memphis, TN 38119, USA
    Pancreas 42:32-6. 2013
  5. doi request reprint Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer
    Lee S Schwartzberg
    Accelerated Community Oncology Research Network, 1770 Kirby Pkwy, Suite 400, Memphis, TN 38138, USA
    Support Care Cancer 17:1081-8. 2009
  6. doi request reprint Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study
    Lee S Schwartzberg
    Accelerated Community Oncology Research Network, 1770 Kirby Parkway, Suite 400, Memphis, TN, 38138, USA
    Support Care Cancer 17:91-8. 2009
  7. doi request reprint Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab
    Lee S Schwartzberg
    West Clinic, Memphis, Tennessee, USA
    Clin Cancer Res 19:2745-54. 2013
  8. doi request reprint Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases
    Mark S Walker
    ACORN Research, LLC, Memphis, TN, USA
    J Med Econ 16:179-89. 2013
  9. pmc Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer
    Mark S Walker
    ACORN Research, LLC, Memphis, TN, USA
    BMC Res Notes 5:314. 2012
  10. pmc Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation
    Mark S Walker
    ACORN Research, LLC, Memphis, TN, USA
    Ther Adv Hematol 2:129-39. 2011

Detail Information

Publications24

  1. ncbi request reprint Controversies in the measurement of daytime sleepiness
    Edward J Stepanski
    Sleep Med Rev 6:79-81. 2002
  2. pmc Improving the utility of interpreting sleep fragmentation
    Edward J Stepanski
    Accelerated Community Oncology Research Network, Memphis, TN 38138, USA
    J Clin Sleep Med 3:275-6. 2007
  3. pmc The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer
    Edward J Stepanski
    Accelerated Community Oncology Research Network, 1770 Kirby Parkway, Suite 400, Memphis, TN 38138, USA
    J Clin Sleep Med 5:132-6. 2009
    ....
  4. doi request reprint The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting
    Edward J Stepanski
    ACORN Research, LLC, Memphis, TN 38119, USA
    Pancreas 42:32-6. 2013
    ....
  5. doi request reprint Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer
    Lee S Schwartzberg
    Accelerated Community Oncology Research Network, 1770 Kirby Pkwy, Suite 400, Memphis, TN 38138, USA
    Support Care Cancer 17:1081-8. 2009
    ..The endpoints were PCM index scores, hospitalization during treatment, and the number of clinic visits during treatment...
  6. doi request reprint Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study
    Lee S Schwartzberg
    Accelerated Community Oncology Research Network, 1770 Kirby Parkway, Suite 400, Memphis, TN, 38138, USA
    Support Care Cancer 17:91-8. 2009
    ..This study was conducted to evaluate the impact of IRs on staff time and costs among patients receiving an initial infusion of cetuximab (Erbitux) and rituximab (Rituxan)...
  7. doi request reprint Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab
    Lee S Schwartzberg
    West Clinic, Memphis, Tennessee, USA
    Clin Cancer Res 19:2745-54. 2013
    ..We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab...
  8. doi request reprint Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases
    Mark S Walker
    ACORN Research, LLC, Memphis, TN, USA
    J Med Econ 16:179-89. 2013
    ..This retrospective observational study describes treatment patterns and longitudinal health-related quality-of-life (HRQoL) among metastatic breast cancer patients with bone metastasis from nine community oncology clinics...
  9. pmc Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer
    Mark S Walker
    ACORN Research, LLC, Memphis, TN, USA
    BMC Res Notes 5:314. 2012
    ..Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC...
  10. pmc Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation
    Mark S Walker
    ACORN Research, LLC, Memphis, TN, USA
    Ther Adv Hematol 2:129-39. 2011
    ..The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear...
  11. doi request reprint Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden
    Edward J Stepanski
    Accelerated Community Oncology Research Network, Memphis, TN 38138, USA
    Clin Lung Cancer 10:426-32. 2009
    ..The purpose of this study was to describe treatment use patterns and outcomes with single-agent erlotinib among patients with advanced non-small-cell lung cancer (NSCLC) in the community oncology setting...
  12. pmc Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients
    Mark S Walker
    ACORN Research, LLC, 6555 Quince, Suite 400, Memphis, TN 38119, USA
    Health Qual Life Outcomes 9:46. 2011
    ....
  13. doi request reprint A retrospective study of quality of life in a community sample of patients with early stage breast cancer
    Mark S Walker
    Accelerated Community Oncology Research Network, 1770 Kirby Rd, Suite 400, Memphis, TN 38138, USA
    Breast Cancer Res Treat 115:415-22. 2009
    ..Study findings suggest that patients show improvement in some areas after recurrence, but generally do not recover previous levels of QoL...
  14. doi request reprint Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    Todd D Tillmanns
    The West Clinic, 100 N Humphreys Blvd, Memphis, TN 38120, USA
    Gynecol Oncol 128:221-8. 2013
    ..We examined the safety and efficacy of combining bevacizumab with albumin-bound (ab-) paclitaxel to treat patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinoma...
  15. doi request reprint Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer
    Paul J E Miller
    ACORN Research, LLC, Memphis, TN, USA
    J Med Econ 16:1179-89. 2013
    ..Little is known, however, about the value patients place on avoiding various aspects of CINV. The current study helps fill this gap in the literature...
  16. doi request reprint Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer
    Lee S Schwartzberg
    Accelerated Community Oncology Research Network, Memphis, TN 38138, USA
    Breast 18:78-83. 2009
    ..Tamoxifen patients who switched to AIs tended to do so following clinical guidelines for use of AIs. Interview results showed that more anastrozole than tamoxifen patients cited side effects as the reason for switching...
  17. ncbi request reprint Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting
    Barry V Fortner
    Supportive Oncology Services, Memphis, TN Accelerated Community Oncology Research Network, Memphis, TN West Clinic, Memphis, TN
    Support Cancer Ther 4:233-40. 2007
    ..The addition of bevacizumab did not appear to increase symptom burden...
  18. ncbi request reprint Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences
    Lee S Schwartzberg
    Accelerated Community Oncology Research Network, Memphis, TN 38138, USA
    Support Care Cancer 16:393-8. 2008
    ..This study represents one of the first attempts to describe the clinical consequences of severe infusion reactions associated with MoAb treatment...
  19. ncbi request reprint The effect of sleep fragmentation on daytime function
    Edward J Stepanski
    Sleep Disorder Service and Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Sleep 25:268-76. 2002
    ..Ideally, clarification of these measurement issues will lead to an improved understanding of sleep structure and the mechanism through which sleep fragmentation impacts daytime function...
  20. ncbi request reprint The scoring of arousal in sleep: reliability, validity, and alternatives
    Michael H Bonnet
    Dayton Department of Veterans Affairs Medical Center, OH 45428, USA
    J Clin Sleep Med 3:133-45. 2007
    ..Additional refinement of arousal scoring will provide improved insight into sleep pathology and recovery...
  21. ncbi request reprint Sleep fragmentation, sleep deprivation, or both
    Edward J Stepanski
    J Clin Sleep Med 2:479; author reply 480. 2006
  22. ncbi request reprint Emerging research on the treatment and etiology of secondary or comorbid insomnia
    Edward J Stepanski
    Department of Behavioral Sciences, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA
    Sleep Med Rev 10:7-18. 2006
    ..A revised model is needed to understand insomnia that is comorbid with medical and/or psychiatric illness, in addition to re-evaluating standard treatment protocols for comorbid insomnia...
  23. ncbi request reprint Daytime sleepiness and alertness in patients with Parkinson disease
    Suzanne Stevens
    Rush University Medical Center, Chicago, IL 60612 3833, USA
    Sleep 27:967-72. 2004
    ..The goal of the study was to objectively measure daytime sleepiness and alertness in patients undergoing treatment for idiopathic Parkinson disease (PD) and assess potential contributing factors...
  24. ncbi request reprint The case for trait determinants of arousal and sleepiness
    Edward J Stepanski
    Sleep 28:664-5. 2005